From genetics to genomics
Between the elucidation of DNA sequence in 1953 and completion of the draft sequence of the human genome in 2001, 62 108 the new discipline of genomics was born, studying the functions and interactions of all genes in a systematic fashion, including their interaction with environmental factors. Using large-scale experimental methodologies and statistical analyses, functional genomics aims to analyse the regulation of gene expression in response to changes in physiological parameters, whereas the goal of structural genomics is to determine the three-dimensional structures of proteins. The conceptual quantum leap from genetics to genomic medicine began with the identi®cation of a variable stretch of DNA (i.e. a polymorphism) near the human b-globin gene associated with the sickle-cell mutation, 56 followed by the suggestion that the location of genes could be predicted in given kindreds by their genetic linkage to a variant, 11 equivalent to gene mapping. The advent of positional cloning in the 1980s gave a new boost to the task of identifying candidate disease genes, 24 allowing the isolation and characterization of a given gene once its location was approximately known without presupposing any information about the gene product. Using this strategy, roughly 1200 disease genes have been identi®ed and characterized, among which many are associated with cardiovascular diseases. 10 Although monogenic cardiovascular disorders are uncommon, elucidating the mechanisms by which single genes can cause disease has clari®ed our understanding of the molecular basis of human genetic diseases, leading to a better appreciation of the pathophysiology of more common cardiovascular diseases like atherosclerosis, coronary artery disease (CAD), hypertension and stroke, which are genetically complex. Such multifactorial (polygenic, complex) diseases characteristically involve an interplay of many genetic variations of molecular and biochemical pathways and their interactions with environmental factors. Many rare genetic variants responsible for monogenic disorders exist in the human population, with these alternative forms of genes (i.e. alleles) typically being evolutionarily recent, highly penetrant (carriers of the mutant gene will likely have the disease), and inherited in simple mendelian fashion (hence, termed mendelian diseases). However, most of the genetic diversity in the population is attributable to more common alleles (i.e. with a frequency of >1% in the general population). According to the`common-variants/commondisease' hypothesis, 25 61 87 it is the common functional allelic variations that probably modulate individual susceptibility to common complex diseases, and the manifestation, severity and prognosis of the disease process. Indeed, the major challenges and ongoing research efforts facing the post-genomic period are to connect the nearly 36 000 genes of mammalian organisms to the genetic basis of complex polygenic diseases and the integrated function of complex biological systems. Genomic research has improved our understanding of all aspects of cardiovascular function, including molecular signalling, contractile mechanisms and energetics, vascular and myocardial structure and remodelling, and electrical activation and propagation. In addition to the identi®cation and construction of single-nucleotide polymorphisms and haplotype maps of the human genome, genomic-based techniques such as high-throughput DNA and protein sequencing, DNA microarray chips for expression pro®ling, mass spectrometry and bioinformatics have been used to identify and validate targets for pharmacological interventions. In this review we describe the various strategies and technical aspects of genomic applications to cardiovascular disease, so that the limitations and potential of these methods can be clearly appreciated.
single-gene (monogenic) cardiovascular diseases such as familial hypercholesterolaemia, 42 hypertrophic cardiomyopathy 92 and long-QT syndrome. 58 Most ongoing research on complex cardiovascular disorders focuses on identifying genetic variants (polymorphisms) that enhance susceptibility to given conditions. Often the design of such investigations is complicated by the presence of multiple risk factors, gene±environment interactions and a lack of even rough estimates of the number of genes underlying such complex traits. There are two general strategies for identifying complex trait loci. The candidate gene approach is motivated by what is known about the trait biologically, and can be characterized as a hypothesis-testing approach because of the biological foundation supporting the proposed candidate genes. The second strategy is a genome scan, in which hundreds/thousands of markers (also called anonymous polymorphisms) uniformly distributed throughout the genome are used to locate genomic regions that may harbour genes in¯uencing the trait variability and to demonstrate the existence of trait genes with detectable effect sizes. This is a hypothesis-generating approach, allowing the detection of previously unknown trait loci.
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Both the candidate gene and the genome scan approaches can be evaluated using one of two fundamental methods of identifying gene variants affecting common diseases: linkage analysis or association studies in human populations. These methods are de®ned below.
Linkage analysis
Linkage analysis is used to identify the chromosomal location of gene variants related to a given disease. This approach has been used successfully to map hundreds of genes for rare, monogenic disorders. New linkage methods are being speci®cally developed and tested for complex disorders since some of the basic assumptions of analysis of traits inherited in classical mendelian fashion are not valid. For example, the nature of complex diseases precludes the use of extended families under the hypothesis that the same disease allele acts in most affected individuals throughout a pedigree. Rather, in complex disease a multitude of genes with rare and/or common alleles creates an apparently chaotic pattern of heterogeneity within and between families. The overall effect of this, together with the potentially weak in¯uence of many loci, is a heavy toll on the statistical power to detect individual contributing genes. This may be the reason why very few scans so far have yielded disease loci that meet genome-wide signi®cance criteria. However, a few positive ®ndings have emerged using this approach. Combining linkage analysis with advanced molecular genetic techniques, the chromosomal location (5q12) of a gene in¯uencing stroke was identi®ed, 43 and risk of myocardial infarction was mapped to a single region on chromosome 14. 13 In addition, successful mapping of many determinants of complex cardiovascular function in male rats has been reported, 99 providing the ®rst rough approximation of genome regions linked to homeostatic control of sodium and water excretion and arterial pressure. However, within these broad regions reside hundreds of genes that may act alone or in concert with each other to determine the relationship to the traits to which they segregate. 26 Modi®cations to current methodology are in development, with the aim of increasing statistical power. Examples are the use of intermediate traits with potentially increased genetic homogeneity, the investigation of admixed populations and the study of linkage disequilibrium over wide genomic regions.
Association studies
As mentioned above, genetic effects on complex cardiovascular disorders are likely to involve multiple susceptibility markers of individually modest importance, thereby limiting the application of linkage analysis. Association studies examine the frequency of speci®c DNA variants in groups of unrelated individuals with disease and unaffected controls. The increased statistical power, 87 and the fact that they do not require family-based sample collections, are the two main advantages of this approach over linkage analysis. Associations between polymorphisms in`anonymous' genes derived by sequencing clones from human cardiovascular complementary DNA (cDNA; synthesized from an RNA template) libraries 67 (hence, termed expressed sequence tags, ESTs), usually encoding proteins of unknown function, can be tested in affected and unaffected individuals using a case±control study design. However, most signi®cant information has been gathered so far from association studies in which prior knowledge of the gene or its protein product existed. The candidate gene approach has been widely used to analyse possible associations between genetic variants and disease outcome, with genes selected because of a priori hypotheses about their potential aetiological role in the disease, based on current understanding of the disease pathophysiology. 102 For example, polymorphisms within the renin±angiotensinogen system and nitric oxide synthase were tested for their association with hypertension. 53 The renin±angiotensin system rapidly became the object of increased attention to identify genomic risk factors in hypertension. 75 Similarly, the possible effects of these polymorphisms on genetic predisposition for CAD 27 103 112 or restenosis after angioplasty 3 57 117 have been extensively investigated. Recent twin studies report that the amount of variability in death from CAD that is attributable to genetic variability (i.e. its heritability) is as high as 0.58. Genetic factors associated with CAD mortality are in operation throughout the entire lifespan, although they seem to be particularly important at early phases of life, as manifested by a decrease in heritability with age. 111 116 Recently, two large-scale association studies have identi®ed gene variants that might affect susceptibility to myocardial infarction. 78 114 Accumulating evidence suggests that speci®c genotypes are associated with organ-speci®c perioperative outcomes, including neurocognitive dysfunction, 104 renal compromise, 18 vein graft restenosis, 77 postoperative thrombosis and vascular reactivity, 63 sepsis, 100 transplant rejection 95 and death (for a review, see Ziegeler and colleagues 118 ) . A summary of the main association studies related to adverse perioperative cardiovascular outcomes is presented in Table 1 .
One of the main weaknesses of the association approach is that, unless the marker of interest`travels with' (i.e. is in linkage disequilibrium with) a functional variant, or the marker allele is the actual functional variant, the tests will have no power to detect and map complex trait loci. Other known limitations of genetic association studies include potential spurious ®ndings resulting from population strati®cation (i.e. admixture of different ethnic or genetic backgrounds in the case and control groups) 16 and multiple comparison issues in the assessment of candidate genes.
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The most reliable method of identifying a true relationship between genetic polymorphisms and disease is replication of ®ndings across different populations or related phenotypes. 102 Poor reproducibility in subsequent studies is one of the main criticisms of the candidate gene association approach. 47 However, a recent meta-analysis identi®ed that underpowered studies are the main contributor to the inconsistent replication, and proposed more stringent statistical criteria to exclude false-positive ®ndings and the design of large collaborative association studies. 70 
Large-scale gene expression pro®ling in cardiovascular disease
Focusing on the primary genetic defect using a reductionist approach to elucidate the causes of cardiovascular diseases has led to limited insight into the resultant complex pathophysiology, especially in terms of identifying novel therapeutic targets. However, our understanding of the molecular pathologies at work in cardiovascular disease is currently undergoing a paradigm shift as the need to describe the overall regulatory networks and interplay of different organ systems, cell types and even subcellular compartments and organelles has become apparent. 60 This has led the scienti®c community to begin exploring and quantifying the transcriptome ± de®ned as the assembly of messenger RNAs associated with the cellular response to stress and disease. At a cellular level, any injurious stimulus triggers adaptive stress responses determined by quantitative and qualitative changes in interdigitating cascades of biological pathways interacting in complex, often redundant ways. 90 Given these complex interconnections, the`single gene' (or protein product) paradigm is insuf®cient to adequately describe, for instance, the myocardial response to severe systemic stimuli such as cardiac surgery with cardiopulmonary bypass. 21 Instead, myocardial injury might better be de®ned by patterns of altered gene and/or protein expression, 22 91 97 which can then be compared during disease development and over the course of disease progression. 19 It is hoped that the integration of information from genome-wide differential expression pro®ling, at a variety of time points and phenotypes across different experimental conditions, with other types of genomic information will enable a better understanding of gene regulatory networks and their malfunction in cardiovascular disease. Although cardiovascular genomic analysis is most commonly focused on heart failure, its application to more acute settings, such as myocardial injury and protection, perioperative outcomes and the stress response of the pulmonary vascular system, is gaining popularity. Several methods are currently in use for large-scale gene expression pro®ling, including differential display, 66 EST identi®cation and sequencing, 31 67 serial analysis of gene expression (SAGE) 107 and microarray analyses using either cDNA-or oligonucleotide-based chips. Of these, microarray technologies have revolutionized the analysis of gene expression changes in biological events 20 and in complex diseases, 65 by simultaneously examining the expression of many thousands of transcripts in a single experiment. Computational analyses of the vast amounts of data thus generated include special algorithms that enable the identi®cation of global patterns of gene expression and grouping genes into expression clusters. Investigating the relationship between such clusters of candidate genes provides greater insight into their potential biological relevance to cardiovascular diseases than simple comparisons of up-and downregulated genes.
32 84 Below, we offer a brief overview of microarray studies that have helped to decipher some of the transcriptional regulatory networks underlying cardiovascular disease.
Genomic approach to heart failure
Congestive heart failure represents the ®nal common pathway of almost any disease or injury that results in cardiac cell and tissue damage. Initial events such as myocardial infarction, hypertensive pressure overload or in¯ammation result in the activation of remodelling processes, de®ned as genome expression, and molecular, cellular and interstitial changes manifested clinically as changes in the size, shape and function of the heart after cardiac injury. 23 While being a homeostatic adaptive response at ®rst, sustained cardiac hypertrophy and remodelling may over time become maladaptive, eventually leading to heart failure. The progression from compensated cardiac hypertrophy to decompensated heart failure is accompanied by marked changes in the expression of a host of genes preferentially expressed in the myocardium. Identifying possible aetiological and speci®c markers for early cardiac decompensation and progression to end-stage heart failure represents the target for genomic-based studies. 51 Numerous investigators have used microarrays or other large-scale expression pro®ling technologies, such as subtractive hybridization 33 55 or genecalling 94 to elucidate transcriptional pro®les in experimental models of myocardial infarction, 54 71 91 97 myocarditis 105 and various ventricular hypertrophy models.
5 38 69 Differential expression patterns have also been identi®ed in myocardial samples from heart failure patients (end-stage hypertrophic, ischaemic and dilated cardiomyopathies).
6 51 115 While comparison of these results is dif®cult because of differences in the technology used, experimental conditions, data analysis and tissue types, some consensus can be found. Examples include induction of the atrial and brain natriuretic peptide (ANP and BNP) genes and extracellular matrix genes in cardiac hypertrophy, and induction of genes involved in stress response, in¯ammation and wound healing in different models of myocardial infarction. Novel sets of differentially expressed genes, previously not implicated in the disease under study, are being identi®ed. 38 115 The number of genes expressed in the cardiovascular system has been estimated at between 21 000 and 27 000, 31 and cardiovascular-based cDNA arrays (CardioChips) have been developed to facilitate the identi®cation of cardiac-speci®c genetic markers. 6 91 97 105 Of note, the high end of the estimated number of genes expressed in the cardiovascular system is very close to the full complement of genes encoded by the entire genome. This supports the idea that the majority of genes in the human genome are involved in the normal maintenance and physiology of an organ regardless of its speci®c function, while only a small proportion are allocated to cell-speci®c functions. 31 Determining and cataloguing such tissuespeci®c gene expression pro®les in response to different stimuli to the heart will lead to the accumulation of a compendium of cardiac gene expression. 50 This can be subsequently used to develop new disease classi®cation systems and to identify the diverse targets affected by a therapeutic intervention. 48 Identi®ed genes of interest can be added as possible`unbiased' candidate genes to enhance future association studies. However, before such use, quality assurance protocols are required to validate microarray results. These include experiment replication, selection of cut-off values used to identify differentially expressed genes, and con®rmation of results by alternative methods (quantitative reverse transcriptase polymerase chain reaction, northern blotting or in situ hybridization). Finally, every new hypothesis has to be further tested through either gain-or loss-of-function studies in biological systems (such as transgenic overexpression, dominantnegative, antisense or gene targeting strategies), in order to establish a causal relationship of the change in gene expression with the disease ± one gene at a time. 89 
Genomic approach to myocardial ischaemia and cardioprotection
Several studies have pro®led myocardial gene expression in the ischaemic heart, demonstrating alterations in the expression of immediate-early genes such as c-fos, junB 12 30 and genes coding for calcium-handling proteins (calsequestrin, phospholamban), 30 37 extracellular matrix and cytoskeletal proteins. 91 97 Subtractive hybridization ± an unbiased method for detecting transcriptionally and posttranscriptionally regulated genes ± was used to analyse expression patterns in stunned myocardium and identi®ed upregulation of transcripts associated mechanistically in cytoprotection (heat shock proteins), resistance to apoptosis and cell growth, as well as previously uncharacterized genes. 33 Microarray technology has also been utilized in the quest for novel cardioprotective genes, 69 98 with the ultimate goal of devising strategies to activate these genes and prevent myocardial injury. Preconditioning is one of the wellstudied models of cardioprotection, which can be induced by diverse triggers including intermittent ischaemia, osmotic or redox stress, heat shock or toxins. Although acute preconditioning does not require new gene synthesis, 106 delayed preconditioning depends on enhanced transcription of genes that lead to cardioprotection. The main functional categories of genes identi®ed as potentially involved in cardioprotective pathways include a host of transcription factors, heat shock proteins, antioxidant genes (superoxide dismutases, haem-oxygenase, glutathione peroxidase) and growth factors. Results from transgenic studies have also suggested that, depending on the level and duration of expression, certain genes (e.g. protein kinase C-epsilon) can have either myocardial protective or hypertrophic effects. 79 A preliminary step in elucidating which genes are causally involved in cardioprotection would be to determine patterns of genes expressed in a coordinated manner that are shared across different models of cardioprotection, for example preconditioning, endogenous protection (male/female differences) or transgenic animals.
Genomic approach to atherogenesis
Several studies have analysed gene expression pro®les in different types of human atherosclerotic lesions 4 46 or in cultured cells 93 and animal models of atherogenesis 72 113 using cDNA microarrays. Results have validated genes already known to be involved in the atherosclerotic process (e.g. apoE, TIMP, CD68), and identi®ed sets of novel differentially expressed transcripts (e.g. ICAM-2, PIM-2, ECGF 1). 4 46 Genes potentially involved in rupture of human atherosclerotic plaques (e.g. periphilin) have been detected using subtraction hybridization and microarrays. 35 Activation of vascular smooth muscle cells followed by proliferation and migration are the key pathophysiological factors in the development of post-angioplasty restenosis, vein graft failure and transplant arteriopathies. Speci®c genes expressed in activated human smooth muscle cells, 28 graft neointima 41 and stenotic aortocoronary vein grafts 45 have been described using large-scale gene expression pro®ling methods. Such changes in gene expression underlie both adaptive and pathophysiological responses that allow vascular cells to remodel, form new vessels or progress to apoptosis. A set of differentially expressed genes in aortic media as compared with vena cava media has been identi®ed using cDNA microarrays, 2 adding to the understanding of molecular phenotypic differences between arteries and veins. Also, a number of genomic-based studies have focused on alterations in vascular gene expression in response to various biomechanical perturbations (shear stress, pulsatile¯ow). A summary of these studies separated by speci®c vascular wall cellular components is presented in Table 2 .
Limitations of gene expression pro®ling
Although newer Af®metrix high-density oligonucleotide microarrays (GeneChipÔ) contain more than 39 000 transcript variants, a major limitation of the microarray technology remains the limited number of genes present on the array, and the fact that genome-wide chips are still unavailable for most species. In studies utilizing tissues made up of heterogeneous cell populations, analysis tools must be used to unpick the tissue complexity, or isolation of cell types must be performed in a manner likely to preserve in vivo expression patterns. For example, a recently developed technique called laser-capture microdissection allows very small cell populations or even single cells to be dissected. Most importantly, expression studies alone cannot prove function. The transcriptome is not fully representative of the proteome (the complete complement of proteins encoded by the genome), since many transcripts are not being actively targeted for translation, 1 as evidenced recently with the concept of gene silencing by RNA interference. 68 Furthermore, alternative splicing, posttranslational modi®cations and protein±protein interactions responsible for biological function 74 remain undetected. Finally, integration and comparison of results is dif®cult, especially across species and platforms. To address this Oxidized-LDL cDNA microarray Downregulation of cell cycle progression genes, induction of nuclear receptors 93 Mechanical strain cDNA microarray Upregulation of early response genes 76 problem, the National Heart, Lung, and Blood Institute (NHLBI) has launched the Programs of Genomic Applications (PGA), to develop information, tools and resources to link genes to biological function on a genomic scale, in order to advance scienti®c research related to heart, lung, blood and sleep disorders (http://www.nhlbi.nih.gov/ resources/pga/). In spite of their limitations and only when coupled with richly annotated comparative databases, DNA microarrays have the potential to become useful tools in cardiovascular disease classi®cation, prediction of treatment responses and prognosis, and identi®cation of novel therapeutic targets.
Genome±Proteome±Physiome/Cardiome± Phenome
The Human Genome Project provides the sequence of nucleotides, localization of genes and amino acid sequence in encoded proteins. However, less than 5% of the human genome represents DNA whose sequence ultimately encodes a protein. Although regulatory sequences and boundaries between the coding (i.e. exons) and non-coding (i.e. introns) regions of the genes are now being recognized and investigated, reaching the goals of functional genomics would require detailed knowledge of regulatory networks of gene expression as well as developmental and metabolic pathways. As mentioned above, microarray studies have revealed that many concurrently regulated genes share the same biochemical pathway and that cellular states may be associated with distinct and unique transcriptional pro®les. 49 These studies have provided a framework on which proteome analyses are based. Proteomics complements genome-based approaches by enabling the identi®cation and characterization of differential protein expression, turnover and localization, post-translational modi®cations (e.g. addition of sugar moieties or lipid attachments to a protein), and interaction with other biological molecules, thus providing new insights into the complex cellular processes involved in cardiovascular dysfunction. To this end, several human cardiac protein databases have been established, 81 and proteome analyses in various human cardiomyopathies 59 88 and animal models of heart disease 44 110 have been reported. The potential for`protein chips' to function as versatile and rigorous high-throughput methods for proteomic analyses is the object of intense investigation. Other more recent functional genomic and proteomic approaches include protein±protein, protein±DNA or other`component± component' interaction mapping (interactome), systematic phenotypic analyses (phenome) and transcript or protein three-dimensional localization mapping (localizome). 40 To overcome the intrinsic limitations of all individual`-omic' approaches, integration of data obtained from several distinct approaches using systems biology strategies has been proposed. This may lead to better functional annotations for the gene products and functional relationships between them, and allow the formulation of relevant biological hypotheses, which can subsequently be tested using either synthetic biology or mathematical modelling of complex signalling networks. 40 Such integrative approaches to speci®cally study cardiovascular function (the Cardiome Project) have already been outlined. 7 Furthermore, the cardiovascular community needs to wrap the pro®ling data within the biological phenomenology, the so-called`phenome' in which the model under study is completely characterized in terms of the changes at the cellular, biochemical, organ and system level (Fig. 1) . 60 
Conclusion
Future trends and challenges in cardiovascular genomics are still being de®ned, but mainly concern interdisciplinary studies designed to combine an analytical system approach, mathematical modelling and engineering principles with the molecular and genetic factors and stimuli and the macroscale interactions that determine cardiovascular function. This may in turn lead to a personalized approach towards medicine and preventative health care. Genomic and proteomic approaches are rapidly becoming platforms for all aspects of drug discovery and development, from target identi®cation and validation to individualization of drug therapy. An integrative systems biology approach will provide a quantitative and mechanistic description that uni®es signalling networks in cardiovascular disease and will identify critical regulatory nodes for therapeutic manipulation.
aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. 
